Dogwood Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Dogwood Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- DWTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001818844
Board of directors
-
David R. Keefer · DirectorSince 2023
-
Gregory Scott Duncan · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
John C. Thomas · DirectorSince 2023
-
Kean Meng Melvin Toh · DirectorSince 2024
-
La Rosa Abel De · DirectorSince 2023
-
Richard Alan Burch · DirectorSince 2023
-
Richard James Whitley · DirectorSince 2023
-
William Pridgen · DirectorSince 2023
-
Ying Choi Alan Abel Yu · DirectorSince 2024
Chief executives
Gregory Scott Duncan
· CHIEF EXECUTIVE OFFICER
Dates unknown
Board connections
1 of this board's directors also sit on 1 other board.
- via Gregory Scott Duncan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 21, 2025 | Conjoint Inc. Director, 10% owner, See Remarks | Derivative conversion | +21,610,950 | — | — |
| Nov 21, 2025 | Conjoint Inc. Director, 10% owner, See Remarks | Derivative conversion | +2,842,638 | — | — |
| Aug 21, 2023 | William Pridgen Director | Open-market purchase | +15,335 | $1.30 | $19,936 |
| Aug 17, 2023 | Gregory Scott Duncan Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +25,000 | $1.25 | $31,250 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.